MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

Table 3 Associations between clinical and pathologic characteristics (Table 1) and ISH parameters and pCR

Parameter^a		Mean age ± SD	Mean size, largest (mm) ± SD	Stage		ER IHC		PR IHC		Mean ERBB2/cell	Mean ERBB2/CEN17
Parameter^a		Mean age ± SD	Mean size, largest (mm) ± SD	II	III	pos	neg	pos	neg	Mean ERBB2/cell	Mean ERBB2/CEN17
MET/CEN7 gain or loss	high	59.3 ± 13.4	39.4 ± 16.6	8	7	9	6	5	10	10.6 ± 5.8	4.9 ± 2.3
	low	47.0 ± 13.0	51.2 ± 18.6	3	6	7	2	7	2	11.9 ± 5.6	6.9 ± 4.0
	p	0.041	0.14	0.42		0.66		0.09		0.59	0.19
Ki-67	high	54.8 ± 14.8	41.6 ± 15.4	9	13	14	8	11	11	13.1 ± 5.5	7.0 ± 3.8
	low	46.0 ± 10.7	57.2 ± 21.6	2	3	4	1	3	2	5.6 ± 2.0	2.9 ± 0.7
	p	0.16	0.19	1.00		0.64		1.00		<0.0001	<0.0001
MET/CEN7 gain or loss AND Ki-67	high	61.5 ± 12.9	37.2 ± 14.9	7	6	7	6	4	9	11.2 ± 6.0	5.1 ± 2.4
	low	46.5 ± 11.8	51.7 ± 18.7	4	7	9	2	8	3	11.1 ± 5.4	6.2 ± 3.9
	p	0.0071	0.051	0.44		0.210		0.10		0.97	0.43
PTEN gain	high	55.6 ± 10.1	40.6 ± 16.7	2	3	2	3	2	3	15.3 ± 4.8	7.0 ± 2.9
	low	49.3 ± 14.1	46.8 ± 17.7	9	11	15	5	13	7	10.3 ± 5.7	5.8 ± 4.1
	p	0.28	0.49	1.00		0.28		0.36		0.83	0.50
pCR	yes	56 ± 15.0	39.5 ± 15.5	8	7	8	7	5	10	13.3 ± 5.7	6.8 ± 3.8
	no	48.9 ± 13.6	46.4 ± 20.0	4	10	12	2	11	3	9.9 ± 5.6	5.2 ± 3.7
	p	0.19	0.31	0.26		0.11		0.025		0.11	0.38

^a p probability calculated using Fischer’s Exact test on contingency tables (stage, ER IHC, PR IHC) or using t-test for comparison of age, tumor size, ERBB2/cell, and ERBB2/CEN17, as executed using JMP Statistical Software. All calculations use parameter cutoffs specified in Table 2

ISSN: 1471-2407